AVAna Maria Valencia-Hernandez

Ana Maria Valencia-Hernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Maria Valencia-Hernandez has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Kupz

    James Cook University

    3 shared publications
  • Guangzu Zhao

    Australian Institute of Tropical Health and Medicine, James Cook University, Cairns & Townsville, QLD, Australia

    3 shared publications
  • Harindra Darshana Sathkumara

    Australian Institute of Tropical Health and Medicine, James Cook University, Cairns and Townsville, Queensland, Australia

    3 shared publications
  • Socorro Miranda-Hernandez

    Australian Institute of Tropical Health and Medicine, James Cook University, Cairns and Townsville, Queensland, Australia

    3 shared publications
  • Daniel Fernandez-Ruiz

    Affiliations Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia, Department of Molecular Medicine, Faculty of Medicine & Health, School of Biomedical Sciences, The University of New South Wales, Sydney, New South Wales, Australia, UNSW RNA Institute, The University of New South Wales, Sydney, New South Wales, Australia

    2 shared publications
  • Julia Seifert

    Australian Institute of Tropical Health and Medicine, James Cook University, Cairns & Townsville, QLD, Australia

    2 shared publications

Latest Publications

  • Antigen-experienced airway CD8 + effector memory T cells promote a detour pathway for mycobacterial killing in the spleen

    by Julia Seifert, Visai Muruganandah, Socorro Miranda-Hernandez, Harindra D. Sathkumara, Ana Maria Valencia-Hernandez, Saparna Pai, Andreas Kupz

    A 3-week delay in the onset of T cell immunity to Mycobacterium tuberculosis ( Mtb ) infection compromises lung bacterial control, resulting in tuberculosis (TB). Restoring T cell function is a priority. We identified how airway CD44 + CD62L − KLRG1 + CD8 + effector memory T cells (T EM ) in the lung enhance mycobacterial clearance via the spleen. Unexpectedly, a secondary immune response following repeated exposure of mice to Bacille Calmette-Guérin generated lower numbers of T EM versus primary. Paradoxically, lower numbers correlated with faster bacterial clearance, due to enhanced trafficking of secondary T EM to the spleen, where they responded to antigen. Further, secondary T EM recruited dendritic cells, which accelerated bacterial translocation from the lung to the spleen. Treating mice with a threshold number of airway-derived secondary T EM significantly reduced Mtb burden in the lung and spleen. Notably, Mtb killing was expedited by at least 15 days. Repeated antigen encounter bypassed priming requirements and enhanced T EM durability, uncovering a spleen-centered protective mechanism with implications for improved TB vaccines and therapies.

  • Open Access

    mRNA-Based Prime-And-Pull Vaccination Combines the Benefits of Subcutaneous and Respiratory BCG Vaccination

    by Ana Maria Valencia-Hernandez, Guangzu Zhao, Julia Seifert, Harindra D. Sathkumara, Socorro Miranda-Hernadez, Munish Puri, Andreas Kupz

    Background: Tuberculosis remains a leading cause of death from infectious disease worldwide, and the limited efficacy of Bacille–Guérin (BCG) vaccination against adult pulmonary tuberculosis highlights the need for improved vaccines. Although mucosal BCG vaccination enhances lung immunity, safety concerns associated with pulmonary delivery of live-attenuated mycobacteria limit its clinical translation.Methods: We developed a prime-and-pull vaccination strategy in which systemic immunity was established by subcutaneous BCG vaccination followed by the induction of local lung immunity through mucosal administration of lipid nanoparticle-formulated multi-antigen mRNA. Immunogenicity, inflammatory responses, safety, and protective efficacy were evaluated in murine models of tuberculosis.Findings: Pulmonary delivery of lipid nanoparticle-formulated mRNA induced antigen-specific polyfunctional T-cell responses in the lung while eliciting minimal inflammatory cell infiltration compared with mucosal BCG vaccination. Following BCG priming, the multi-antigen mRNA boost generated robust local immune responses and was well tolerated. In a murine Mycobacterium tuberculosis challenge model, the prime-and-pull strategy conferred protection comparable to mucosal BCG vaccination while avoiding the safety concerns associated with pulmonary administration of live BCG.Interpretation: These findings demonstrate that mRNA-mediated pulmonary immune boosting following parenteral BCG vaccination is a promising and modular strategy to enhance tuberculosis vaccine efficacy while preserving the established safety profile of systemic BCG vaccination. This approach provides a translational platform for next-generation tuberculosis vaccines.

  • Open Access

    mRNA-based prime-and-pull vaccination combines benefits of subcutaneous and mucosal BCG vaccination

    by Ana Maria Valencia-Hernandez, Guangzu Zhao, Julia Seifert, Harindra D. Sathkumara, Socorro Miranda-Hernadez, Munish Puri, Andreas Kupz

    Pulmonary vaccination has been proposed as a strategy to improve protection against tuberculosis, due to the generation of immune cells that more efficiently survey and eliminate infected cells within the lung. However, uncontrolled replication and excessive inflammation associated with mucosal delivery of live-attenuated vaccines highlight the need for alternative strategies that balance efficacy and safety. Here, we describe a prime-and-pull vaccination approach in which systemic immunity is established by subcutaneous BCG vaccination, followed by the induction of local lung immunity through mucosal delivery of lipid nanoparticle–formulated multi-antigen mRNA. Proof-of-concept studies using a model antigen demonstrated the induction of polyfunctional antigen-specific T cells in the lung with minimal inflammatory cell infiltration, compared with mucosal BCG vaccination. Eight Mycobacterium tuberculosis - and BCG-derived proteins were subsequently selected to generate four multi-antigen mRNA constructs. In vivo vaccination and challenge experiments demonstrated that this prime-and-pull strategy is well tolerated and confers protective immunity against tuberculosis in a murine model. Collectively, these data support a modular mRNA-based prime-and-pull vaccination strategy as a translational approach that bridges the improved immunogenicity and efficacy of mucosal BCG vaccination with the safety profile of parenteral BCG administration. Graphical

  • A Modular Self‐Assembling and Self‐Adjuvanting Multiepitope Peptide Nanoparticle Vaccine Platform to Improve the Efficacy and Immunogenicity of BCG

    by Guangzu Zhao, Harindra D. Sathkumara, Socorro Miranda‐Hernandez, Julia Seifert, Ana Maria Valencia‐Hernandez, Munish Puri, Wenbin Huang, Istvan Toth, Norelle Daly, Mariusz Skwarczynski, et al.

    After more than a century since its initial development, Bacille Calmette‐Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB). Subunit boosters are considered a viable strategy to enhance BCG efficacy, which often wanes in adolescence. While many studies on booster subunit vaccines have concentrated on recombinant proteins, here we developed a novel modular peptide‐based subunit vaccine platform that is flexible, cold‐chain independent and customizable to diverse circumstances and populations. Each individual peptide building block consists of a linear arrangement comprising a 15‐leucine self‐assembly inducer moiety, a Mycobacterium tuberculosis (Mtb) target epitope and an human leukocyte antigen E (HLA‐E) binding moiety, with each moiety separated by a triple lysine spacer. The building blocks, in any combination, are able to form a multiepitope nanoparticle. Six Mtb epitopes were selected to produce the self‐assembling and self‐adjuvating peptide‐based TB nano‐vaccine candidate PNx6. In vivo vaccination‐challenge experiments demonstrated that subcutaneous boost of parenteral BCG immunization with PNx6 significantly enhanced its immunogenicity and improved its protective efficacy in a murine model of TB by more than 5‐fold. This study presents evidence that purely amphiphilic peptides self‐assemble into self‐adjuvating nanoparticles with appropriate size and morphology for TB vaccination with great potential for a multitude of other diseases.


  • Open Access

    Resident Memory T Cells and Their Role within the Liver

    by Sonia Ghilas, Ana-Maria Valencia-Hernandez, Matthias H. Enders, William R. Heath, Daniel Fernandez-Ruiz

    Immunological memory is fundamental to maintain immunity against re-invading pathogens. It is the basis for prolonged protection induced by vaccines and can be mediated by humoral or cellular responses—the latter largely mediated by T cells. Memory T cells belong to different subsets with specialized functions and distributions within the body. They can be broadly separated into circulating memory cells, which pace the entire body through the lymphatics and blood, and tissue-resident memory T (TRM) cells, which are constrained to peripheral tissues. Retained in the tissues where they form, TRM cells provide a frontline defense against reinfection. Here, we review this population of cells with specific attention to the liver, where TRM cells have been found to protect against infections, in particular those by Plasmodium species that cause malaria.


  • Glycolipid-peptide vaccination induces liver-resident memory CD8 + T cells that protect against rodent malaria

    by Lauren E. Holz, Yu Cheng Chua, Maria N. de Menezes, Regan J. Anderson, Sarah L. Draper, Benjamin J. Compton, Susanna T. S. Chan, Juby Mathew, Jasmine Li, Lukasz Kedzierski, et al.

    Glycolipid-peptide conjugate vaccines protect against rodent malaria by generating large numbers of liver CD8 + T RM cells.